-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson announced that the US FDA approved RYBREVANT FASPRO™ as the first and only dual-targeted therapy for advanced head and neck cancer.
Share
Listen to the news
Johnson & Johnson announced that the US FDA approved RYBREVANT FASPRO™ as the first and only dual-targeted therapy for advanced head and neck cancer.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending